Schedule 13G ownership disclosure

Lomond Therapeutics Holdings, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 54173L101

Event date: 2024-12-31

Filing-level shares
1,187,500.00
Percent of class
4.0%
  • Mark N. Tompkins

    Shares: 1,187,500.00 · Class: 4.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-014232
Form type
SCHEDULE 13G/A
Filer
Lomond Therapeutics Holdings, Inc.
CIK
CIK 1900520
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub